Award notice Supplies

Spécialités pharmaceutiques à base d'everolimus 5mg et 10mg (voie orale).

Notice published in French. The AI analysis summarises it for you in your language.

Official notice and documents

Public buyer: Healthcare Public Procurement (HeCaPP)
Saint-Gilles\Sint-Gillis
Place of performance: 1000 Bruxelles\Brussel, Brussels-Capital
Amount awarded: €209,276 excl. VAT
Planned end of contract: 15 April 2029
likely re-tender around October 2028
Bids received: 2
Procedure: Open procedure
Any company may submit a bid.
Publication: 2 May 2025
Notice language: French

What is the authority looking for?

Supplies

Spécialités pharmaceutiques à base d'everolimus 5mg et 10mg (voie orale).

Where and when?

1000 Bruxelles\Brussel, Brussels-Capital

Deadline not published in the notice

Site visit and deadline for questions: stated in the specifications, not in the notice.

What budget?

Amount not published in the notice. The AI analysis and comparable tenders give an order of magnitude.

Why is this tender relevant to me?

Create your free account : we compare every tender with your trade and your area.

Can I consider bidding?

The AI analysis extracts the participation conditions, the contractor approval and the required documents. See the analysis and the verdict for your company

Nothing is assumed: what the notice does not say is marked "to check".

What do I need to do?

1. Read the analysis · 2. Check that you meet the conditions · 3. Prepare the response · 4. Submit on the official platform before the deadline.

This tender is no longer open.

AI analysis: go for it or not?

Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.

Create my free account

Unlimited analyses during the 14-day Pro trial, no card needed.

Description

Spécialités pharmaceutiques à base d'everolimus 5mg et 10mg (voie orale).

Awarded to

NOVARTIS PHARMA NV BCE/KBO 0459.093.476

CPV codes

European codes that classify what the contract is about. They are how we find the tenders for your trade.

33600000

Winning prices for comparable contracts

A quarter below: €269,390
Median: €449,863
A quarter above: €962,736

Amounts awarded (excl. VAT) over the last 3 years for 58 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.

Similar contracts already awarded

Contract	Winner	Amount
Farmaceutische specialiteiten op basis van piperacilline/tazobactam, flucloxacilline, linezolid, benzylpenicilline (natrium), vancomycine (hydrochloride), ceftazidime, meropenem (trihydraat), ciprofloxacine en ceftriaxon Healthcare Public Procurement (HeCaPP) · 31 August 2026	Viatris Fresenius Kabi sandoz	€1,646,683
Spécialité pharmaceutique à base de (li)pegfilgrastim Healthcare Public Procurement (HeCaPP) · 18 August 2026	ACCORD HEALTHCARE	€656,000
Spécialités pharmaceutiques à base de glecaprévir/pibrentasvir Healthcare Public Procurement (HeCaPP) · 18 August 2026	Abbvie SA	€2,856,000
spécialités pharmaceutiques à base de solutions de perfusion standard de NaCl 0,9%, de Glucose 5%, de Ringer lactate, de Glucose 10%, de Glucose 5% + NaCl 0,9%, d'eau stérile et de solution d'électrolytes isotonique (sans tampon lactate) et spécialités pharmaceutiques à base de solutions d'irrigation de NaCl 0,9%, de Glycine 1,5% et d'Eau stérile Healthcare Public Procurement (HeCaPP) · 1 July 2026	B. BRAUN MEDICAL BAXTER BELGIUM	€5,294,599
Farmaceutische specialiteiten op basis van fluconazol, voriconazol, anidulafungine, posaconazol en caspofungine Healthcare Public Procurement (HeCaPP) · 29 June 2026	SANDOZ SA Pfizer Fresenius Kabi NV/SA	€186,652

Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 282202-2025.